Develops and sells prescription medicines across immunology, oncology and aesthetics.
AbbVie (ABBV) scores 5.5 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on profitability, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
AbbVie’s returns on capital beat their cost in almost every measured year, by a clear margin: 4 of 5 indicators passed.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
A company that has already absorbed the loss of exclusivity on its largest product is a real test of the framework: growth and predictability record the disruption while profitability stays high. Solvency matters too, because the acquisition that diversified the portfolio was largely debt-funded. The pillar split is where you see whether the replacement is working.
The Quality Score for ABBV stands at 5.5 out of 10 as of October 19, 2026, which puts AbbVie in the solid quality band. This band covers companies that do several things well but not everything, so the pillar detail below matters more than the headline. It rolls AbbVie’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Among the 212 Healthcare companies with a published score, that ranks at the 66th percentile, above the middle of the group. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves AbbVie above the median.
On profitability, AbbVie scores 7.5, a strong reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well above them, at the 88th percentile. Returns and margins at this level leave room to reinvest, absorb a bad year or return cash to shareholders without straining the business.
AbbVie’s solvency score is 5.7 out of 10 (average). Against a median of 6.5 among 150 Healthcare companies, that is below the group and the 38th percentile. Middling solvency says the balance sheet is neither a strength nor a constraint today.
On growth, AbbVie scores 1.8, a weak reading. Its peers have a median of 4.9 across 107 Healthcare companies, which places it well below them, at the 14th percentile. When growth is this low the question is whether it is a pause or a trend, and the history behind the filings is the place to look.
AbbVie’s efficiency score is 5.8 out of 10 (average). Against a median of 6.0 among 200 Healthcare companies, that is in line with the group and the 44th percentile. Efficiency near the median says the operation is neither unusually lean nor unusually capital hungry.
On predictability, AbbVie scores 6.2, an average reading. Its peers have a median of 3.4 across 207 Healthcare companies, which places it well above them, at the 84th percentile. Middling predictability suggests some volatility in the record, enough to read the other pillars with a little caution.
The gap between AbbVie’s best and worst pillar is wide: profitability at 7.5 against growth at 1.8, 5.7 points apart. An average of two readings this different deserves a closer look than the headline number. A profitability lead usually reflects something durable in the business model rather than a good year. Slow growth limits how fast the business can compound, even when everything else is in order.
The pillar with the most room to move the score is growth. If it rose to the median of Healthcare companies, 4.9, AbbVie’s overall score would go from 5.5 to about 6.1. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and AbbVie has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to AbbVie by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading AbbVie scores 5.5 out of 10, which reads as solid quality. Its strongest pillar is profitability, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
AbbVie ranks at the 66th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against AbbVie’s 5.5.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for ABBV are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card